Multiple system atrophy (MSA) is a rare neurodegenerative disorder with substantial knowledge gaps despite recent gains in basic and clinical research. In order to make further advances, concerted international collaboration is vital. In 2014, an international meeting involving leaders in the field and MSA advocacy groups was convened in Las Vegas, Nevada, to identify critical research areas where consensus and progress was needed to improve understanding, diagnosis, and treatment of the disease. Eight topic areas were defined: pathogenesis, preclinical modeling, target identification, endophenotyping, clinical measures, imaging biomarkers, nonimaging biomarkers, treatments/trial designs, and patient advocacy. For each topic area, an expert served as a working group chair and each working group developed priority-ranked research recommendations with associated timelines and pathways to reach the intended goals. In this report, each groups' recommendations are provided.
Glossary α-syn = α-synuclein; MSA = multiple system atrophy; SWOT = strengths, weaknesses, opportunities, and threats.
Multiple system atrophy (MSA) is a rare and devastating neurodegenerative disorder presenting clinically with severe autonomic failure, parkinsonism, cerebellar ataxia, and corticospinal tract signs in varying combinations. 1 MSA is considered an orphan disease with an annual incidence rate of 0.1-3 per 100,000 depending on age and geographic region. [2] [3] [4] [5] The estimated prevalence rates range from 1.9 to 4.9. 4, [6] [7] [8] [9] MSA is a progressive and incurable disease leading to death typically within 9 years after symptom onset. [10] [11] [12] [13] [14] [15] [16] [17] There are substantial knowledge gaps in the scientific understanding of and clinical approach to MSA. The pathophysiology underlying MSA is poorly understood, although abnormal forms of α-synuclein (α-syn) appear to play a key role in the pathogenic neurodegenerative cascade. 18 Diagnostic certainty can be challenging and symptomatic therapies are of limited and transient benefit in alleviating disease burden. 12, 15 Because MSA is a rare disease, international collaboration is critical to generate cohorts of sufficient size for studying and advancing knowledge about this disorder; such global efforts can be difficult to implement. 19 In 2014, an international meeting involving leaders in the field and MSA advocacy groups was convened in Las Vegas, Nevada, to address these issues and develop a roadmap for MSA-related research. A summary of these recommendations is provided below.
Methods
Similar to the development of the 2013 NIH Alzheimer's Disease-Related Dementias Conference, 20 the overall process was divided into planning, preconference, conference, and postconference activities.
Planning
Planning efforts began in early 2014 when the meeting chairs defined the objectives of the meeting. The prespecified goals of the meeting are presented in the table. The 6 objectives were then incorporated into 7 topics, and for each topic a 5-to 6-member working group and chair were designated (see Results). Together with the working group chairs, the meeting chairs and advisory board recruited relevant researchers for each working group.
Preconference
Each working group was tasked with developing a prioritized list of up to 4 recommendations for their topic prior to the meeting. Conference calls were convened for each working group prior to the conference to develop draft recommendations. All recommendations were based on the working group's analysis of current strengths, weaknesses, opportunities, and threats (SWOT analysis) in their research area. The SWOT analysis was summarized and incorporated into a "need" describing the rationale for the recommendation. In addition, a "pathway" was developed to identify the essential items to achieve the recommended goal. Thus, all recommendations had the following predefined structure: recommendation (what?), need (why?), and pathway (how?). Complete full-text final recommendations from each working group are provided in appendix e-1 (links. lww.com/WNL/A22).
Conference
The Global MSA Research Roadmap Meeting was held on November 1-2, 2014, at the Keep Memory Alive Event Center on the campus of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. There were approximately 75 international conference participants representing academia, industry, advocacy groups, and the NIH. Working groups were first charged to discuss and finalize their premeeting working group recommendations during an in-person workshop at the conference. Subsequently, each working group presented their recommendations to the meeting participants, which was followed by an open discussion on the proposed recommendations, their priority levels, and the anticipated timelines.
Postconference
Each working group finalized their recommendations incorporating conference feedback and discussion. Subsequently, a manuscript was developed that included input from the conference chair and co-chairs, advisory panel, and working group chairs.
Results
The primary outcome of the conference is the prioritized MSA research roadmap recommendation list summarized in figures 1 and 2. Estimated timelines and pathways to reach the intended goals were also developed and are summarized in figures e-1 and e-2 (links.lww.com/WNL/A21). Research recommendations are presented by topic area and prioritized as per each working group, incorporating the meeting discussion. The complete working group documents are provided in appendix e-1 (links.lww.com/WNL/A22).
Key themes drawn from the research roadmap recommendations warrant consideration. Preclinical MSA research would benefit from improved understanding of pathogenesis, particularly the development of novel preclinical models that more faithfully reproduce MSA pathology, symptomatology, and progression. Such models would also enable standardized preclinical testing of potential therapies. Clinical research would benefit from improved diagnostic accuracy, particularly for early diagnosis through advances in clinical and biomarker research. Furthermore, and similar to the preclinical recommendations, coordinated and standardized diagnostic and therapeutic approaches were considered essential to facilitate future collaboration and develop and validate outcome measures for future clinical trials.
The Pathogenesis Working Group set 3 research priorities with elucidation of the relationship between oligodendroglial pathology and neuronal death viewed as the primary research area. It was also agreed that additional work on α-syn, through investigation of protein structure, assembly into filaments, and propagation of abnormal structure, would significantly advance the field. Finally, the panel thought that additional investigations in regional anatomic vulnerability to pathology, initiating factors, and changes that precede α-syn accumulation, aggregation, posttranslational modifications, and cell-tocell transmission and their role in driving disease would be warranted. The initiation of projects providing insights into these research priorities were estimated to require at least 3 years and formative work would not be expected to be completed before 2020.
Current in vivo MSA models incompletely replicate the disease process, 21 which may contribute to their failure to predict clinical benefit from attempts at therapeutic intervention. The Preclinical Modeling Working Group ranked the development of novel rodent MSA models incorporating recent findings from nonvertebrate models, in vitro models, as well as human brain tissue studies as top priorities. Thus far, behavioral studies in MSA animal models mainly have focused on motor deficits whereas nonmotor endpoints have not been studied systematically. However, both motor and nonmotor outcomes are pertinent for drug discovery in MSA since patients experience motor impairment along with severe generalized autonomic failure, cognitive deficits, and other nonmotor symptoms. Therefore, the panel identified the characterization of existing transgenic MSA models using nonmotor endpoints, wet biomarkers, and multimodal neuroimaging as another important research priority. MSA genetics and underlying pathogenesis remain poorly understood and the generation of hypothesis-blind models of MSA (i.e., induced pluripotent stem cells) also was considered another top research priority.
The Preclinical Target Development Working Group identified α-syn as the most promising target for future interventional therapies. It was suggested that research should focus particularly on (1) measuring and reducing α-syn pathology in models of oligodendroglial α-syn overexpression for future translation into human trials and (2) identification/validation of biomarkers through bidirectional/iterative feedback with human studies. A close collaboration between preclinical and clinical researchers is critical to facilitate the development of reliable biomarkers; clinical studies often generate hypotheses regarding which biomarkers may hold promise, and preclinical testbeds can then be used to develop specific diagnostic tools. After clinical validation, these newly developed tools may facilitate therapeutic development and improve patient care.
The Clinical MSA Phenotype Working Group noted that it is essential, as with other neurodegenerative disorders, for any effective treatment to be started as early as possible in the disease course. However, the low sensitivity of early clinical diagnosis of MSA means that the disease is typically diagnosed at a time when the pathology is advanced. 22 Therefore, the clinical working group on MSA phenotype concluded that developing a patient-completed clinical questionnaire and physician-confirmed checklist should improve sensitivity of early clinical diagnosis and ranked this objective as their top research priority. The working group recommended developing a detailed operations manual to facilitate the diagnosis of MSA using the current consensus criteria including standardized wording of key clinical questions. 23 As a second step, the development of a clinical score-based aid to diagnose MSA without necessarily requiring sophisticated and costly investigations would be highly warranted.
Improvements in clinical measures were also identified as a research area that requires special attention. The Clinical Outcome Measures Working Group agreed that the development of a valid international rating scale based on the revision and improvement of the existing Unified MSA Rating Scale 24, 25 should be the top research priority, which could be Table Prespecified meeting objectives 1. To develop a roadmap for MSA-related research to provide a framework for therapeutic development from an expanded understanding of the following:
• Molecular pathogenesis
• Preclinical modeling
• Targeting of pathologic development and spread
• Understanding divergence of α-synucleinopathy vs PD
• Disease phenotypes and outcome measures, including global registry
• Disease onset, disease progression, and therapeutic response biomarkers [26] [27] [28] There was consensus that an international registry providing standardized and comprehensive phenotypic data linked to local biobanks/biomaterial collections as well as imaging data would advance the field. Thus, the clinical outcome measure working group defined the creation of a unified dataset for MSA and implementation of an international global registry as their second top research priority.
The Imaging Biomarkers Working Group recognizes that previous studies provide a rich MRI repertoire with potential to be used in diagnosis, natural history, and treatment studies. 29 There is, however, lack of consistent evidence for MRI-based changes in MSA at magnetic fields of 3.0T or higher, scarce evidence for early MRI-based changes, and limited comparability among studies given heterogeneous MRI protocols, study populations, and different segmentation techniques. The working group prioritized the development of standardized protocols for MRI-based diagnostics at current conventional field strengths with exploration of the sensitivity of a multimodal approach (e.g., PET/MRI, multimodal MRI) to disease progression and preclinical diagnosis as their top priority. Another focus area was the development and implementation of functional imaging protocols with currently available tracers to evaluate MSA-related brain networks and dopaminergic integrity using PET and SPECT. Finally, the imaging panel agreed that development of sensitive and reproducible imaging agents to assess molecular aspects of MSA pathology including α-syn aggregation is warranted.
The Non-Imaging Biomarkers Working Group noted that fluid and tissue biomarker data for MSA are sparse, 30 and there is a is a critical need to standardize and validate methods for both cross-sectional and longitudinal studies. The working group prioritized establishing an infrastructure for standardized collection of biofluids (CSF and blood-based) and tissues (standardized skin biopsy; central and autonomic nervous system at autopsy) their top research priority. Another recommendation was the exploitation of ongoing multicenter biomarker cohorts (both existing and future ones) in 2 ways: (1) to determine the profile of candidate, pathologic analytes in patients with MSA through validated testing platforms; and (2) to interrogate specimens in an unbiased manner through complementary strategies for the discovery of potential markers. Further research toward the development of a cutaneous biomarker for MSA by measuring the degree of deposition for pathologic variants of α-syn deposition in cutaneous autonomic nerves was also considered important.
Similar to other group recommendations, the Clinical Treatments and Trials Working Group prioritized the need for developing tools to facilitate earlier diagnosis and for creating biobanking infrastructure dedicated to MSA. In addition, prospective cohort studies to characterize progression rates and sensitivity to change over time of clinical, imaging, and other biofluid markers were ranked as top research priority. Additional recommendations were focused on the development of novel therapies for disease modification and promising symptomatic treatments. It was recognized that advances in preclinical and clinical research as outlined above are needed to facilitate the development of novel treatments.
The Patient Advocacy Working Group highlighted the importance of developing a continuing education program to inform medical and allied health professionals about MSA, along with establishing clinical centers of excellence, as the top priorities. In addition, a funded liaison who works with stakeholders to access funds, cultivate the development of innovative technologies, and nurture collaborative research programs was considered another important goal. A public information structure to develop and disseminate information tailored for advocacy and awareness should be another focus area in the next years. Finally, a collaborative network of relevant, nonmedical organizations would be important to strengthen advocacy and support patient-responsive research.
Discussion
In the last decade, MSA has seen an encouraging increased interest among clinical and experimental scientists, along with improved international collaboration. In this spirit, a dedicated MSA research roadmap meeting that involved global leading MSA researchers was undertaken, with the overarching goal of helping to further coordinate thinking and efforts to enable progress toward clinically meaningful therapeutics. This report reflects the carefully considered recommendations developed collaboratively by a large group of leaders in the field and is intended to be an authoritative (but not the only) source for guiding future research efforts and priorities regarding MSA.
Each of the recommendations in this report provides important research goals on its own. During the conference, differing opinions about the current state and future directions were discussed and, upon agreement, incorporated into the final recommendation. Hence, the prioritized recommendations list reflects a thoughtful, collaborative, and efficient approach to ultimately prevent, stop, or cure MSA. It is important to mention that lower-ranked recommendations in this report do not reflect a lack of importance; inclusion suggests that the research objective is indeed among the top priority items in the field. In addition, these recommendations are not meant to be exclusive. It will be critical to continuously explore new research areas as they emerge, and modify the research roadmap accordingly. In addition, we recognize achievement of these research goals is ambitious and will require not only funding but also the continued commitment of established as well as new investigators in the MSA field. The present recommendations constitute an initial framework for future research efforts in MSA. These goals may be refined in the future, and it is recognized that an overall ranking irrespective of the different areas of research may be useful to the research community and cost-effectiveness is also an important consideration.
Although major knowledge gaps remain, the prerequisites for change are in place: (1) a passionate and committed research community to execute this research plan, (2) a growing international collaborative that encompasses preclinical work as well as clinical research, and (3) a fully dedicated and wellorganized network of advocacy. The rate of progress is limited in part by the rarity of the illness and the available resources, highlighting the vital role of MSA advocacy and collaboration. Our sincere hope is that the Global MSA Research Roadmap recommendations will help to advance research in MSA, broaden the knowledge and awareness of MSA, recruit talented scientists from neighboring disciplines, further raise awareness, and thus allow us as a community to develop effective therapies as quickly as possible for this fatal disease.
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